XHKG
3681
Market cap187mUSD
Oct 09, Last price
1.15HKD
1D
7.48%
1Q
-3.36%
IPO
-74.89%
Name
SinoMab BioScience Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.05%
Rev. gr., 5y
-1.60%
Revenues
0
-100.00%
Net income
-102m
L-44.76%
CFO
-70m
L-46.12%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
SinoMab BioScience Limited is a biopharmaceutical enterprise that specializes in the comprehensive process of discovering, developing, producing, and marketing therapeutic solutions for various immunological disorders. Their approach predominantly involves monoclonal antibody (mAb)-based biologics. A key asset in their portfolio is SM03, an innovative anti-CD22 monoclonal antibody. This drug is currently in Phase III clinical trials for rheumatoid arthritis (RA), with additional clinical investigations underway for other immune-related conditions such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company is also progressing with SN1011, a Bruton's tyrosine kinase inhibitor. This compound is in Phase II clinical trials for pemphigus and has commenced Phase I trials for multiple sclerosis, SLE, and neuromyelitis optica spectrum disorder (NMOSD). Furthermore, SinoMab maintains an active preclinical pipeline. This includes SM17, which targets asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06, intended for RA, SLE, NMOSD, and SS; SM09, in development for NHL and RA; and TNF2, focused on a range of autoimmune diseases. Founded in 2001, SinoMab BioScience Limited is based in Pak Shek Kok, Hong Kong, and conducts its business activities across Mainland China, the Cayman Islands, and Hong Kong.
Key people
Shui On Leung
Chairman of the Board, Chief Executive Officer · since 2003
Jianping Hua
Chief Financial Officer · since 2019
Shanchun Wang
Executive Director · since 2024
Ka Wa Cheung
Research Scientist · since 2010
Ming Hon Yau
Research Project Manager · since 2012
Kwan Yin Siu
Research Scientist · since 2011
Lixin Zhang Auberson
Chief Medical Officer · since 2021
Yuk Yin Chow
Company Secretary · since 2023
Wai Ki Lai
Company Secretary · since 2025
Haigang Chen
Non-Executive Director · since 2019
Xun Dong
Non-Executive Director · since 2019
Zhang Jianmin
Non-Executive Director · since 2023
Xiaosu Wang
Non-Executive Director · since 2024
George Cautherley
Non-Executive Independent Director · since 2019
Ping Cho Hon
Non-Executive Independent Director · since 2019
Chi Sau Lee
Non-Executive Independent Director · since 2025
Chi Ming Lee
Non-Executive Independent Director
Shen Nan
Non-Executive Independent Director · since 2025
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||